299 related articles for article (PubMed ID: 33750796)
1. RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β2.
Wang X; Wang J; Tsui YM; Shi C; Wang Y; Zhang X; Yan Q; Chen M; Jiang C; Yuan YF; Wong CM; Liu M; Feng ZY; Chen H; Ng IOL; Jiang L; Guan XY
Nat Commun; 2021 Mar; 12(1):1518. PubMed ID: 33750796
[TBL] [Abstract][Full Text] [Related]
2. PITX2C increases the stemness features of hepatocellular carcinoma cells by up-regulating key developmental factors in liver progenitor.
Jiang L; Wang X; Ma F; Wang X; Shi M; Yan Q; Liu M; Chen J; Shi C; Guan XY
J Exp Clin Cancer Res; 2022 Jun; 41(1):211. PubMed ID: 35765089
[TBL] [Abstract][Full Text] [Related]
3. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.
Zhong M; Zhong C; Cui W; Wang G; Zheng G; Li L; Zhang J; Ren R; Gao H; Wang T; Li X; Che J; Gohda E
BMC Cancer; 2019 May; 19(1):439. PubMed ID: 31088527
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling.
Long J; Jiang C; Liu B; Dai Q; Hua R; Chen C; Zhang B; Li H
Cancer Lett; 2018 Jun; 423():113-126. PubMed ID: 29196128
[TBL] [Abstract][Full Text] [Related]
5. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.
Ching RHH; Sze KMF; Lau EYT; Chiu YT; Lee JMF; Ng IOL; Lee TKW
Oncotarget; 2017 Apr; 8(14):23507-23516. PubMed ID: 28186991
[TBL] [Abstract][Full Text] [Related]
6. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.
Sun CK; Chua MS; He J; So SK
Neoplasia; 2011 Aug; 13(8):735-47. PubMed ID: 21847365
[TBL] [Abstract][Full Text] [Related]
7. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
[TBL] [Abstract][Full Text] [Related]
8. Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma.
Xiang X; Deng L; Xiong R; Xiao D; Chen Z; Yang F; Liu K; Feng G
Cell Cycle; 2018; 17(11):1310-1318. PubMed ID: 30045663
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
[TBL] [Abstract][Full Text] [Related]
10. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma.
Malfettone A; Soukupova J; Bertran E; Crosas-Molist E; Lastra R; Fernando J; Koudelkova P; Rani B; Fabra Á; Serrano T; Ramos E; Mikulits W; Giannelli G; Fabregat I
Cancer Lett; 2017 Apr; 392():39-50. PubMed ID: 28161507
[TBL] [Abstract][Full Text] [Related]
12. Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma.
Liu B; Fang X; Kwong DL; Zhang Y; Verhoeft K; Gong L; Zhang B; Chen J; Yu Q; Luo J; Tang Y; Huang T; Ling F; Fu L; Yan Q; Guan XY
J Exp Clin Cancer Res; 2022 May; 41(1):182. PubMed ID: 35610614
[TBL] [Abstract][Full Text] [Related]
13. Aquaporin 3 maintains the stemness of CD133+ hepatocellular carcinoma cells by activating STAT3.
Wang Y; Wu G; Fu X; Xu S; Wang T; Zhang Q; Yang Y
Cell Death Dis; 2019 Jun; 10(6):465. PubMed ID: 31197130
[TBL] [Abstract][Full Text] [Related]
14. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
15. HNRNPC downregulation inhibits IL-6/STAT3-mediated HCC metastasis by decreasing HIF1A expression.
Liu D; Luo X; Xie M; Zhang T; Chen X; Zhang B; Sun M; Wang Y; Feng Y; Ji X; Li Y; Liu B; Huang W; Xia L
Cancer Sci; 2022 Oct; 113(10):3347-3361. PubMed ID: 35848884
[TBL] [Abstract][Full Text] [Related]
16. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
[TBL] [Abstract][Full Text] [Related]
17. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.
Cheng BY; Lau EY; Leung HW; Leung CO; Ho NP; Gurung S; Cheng LK; Lin CH; Lo RC; Ma S; Ng IO; Lee TK
Cancer Res; 2018 May; 78(9):2332-2342. PubMed ID: 29483095
[TBL] [Abstract][Full Text] [Related]
18. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Liu ZM; Tseng JT; Hong DY; Huang HS
Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
[TBL] [Abstract][Full Text] [Related]
19. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
20. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
